ANTEOTECH LTD — Investor Presentation 2015

Jul 27, 2015

AACC conference summary and CEO interview

For Immediate Release:

July 28, 2015

==> picture [315 x 91] intentionally omitted <==

Highlights:

• Anteo’s VP of Scientific Affairs, Josh Soldo, presents at the American Association for Clinical Chemistry (AACC) annual conference

• Anteo exhibits in the AACC Clinical Lab Expo

• Dr Geoff Cumming expands upon recent announcements, provides further background to Mr Soldo’s presentation and the AACC conference

Brisbane, Australia – Anteo Diagnostics Limited (ASX:ADO) (“Anteo” or the “Company”), is pleased to release a copy of the presentation that Joshua Soldo will deliver at the AACC OEM Lecture Series on Tuesday 28 July at 10.30am EST, along with an audio interview where Dr Geoff Cumming, discusses recent announcements and provides further context to Josh’s presentation.

Anteo at AACC

This week, Anteo will have a presence at the AACC Conference in Atlanta, Georgia. The AACC conference is recognised as the world’s leading event for laboratory medicine and has 21,000 registrants this year.

Josh Soldo, VP of Scientific Affairs presents

Following a competitive submission process, the abstract submitted by Anteo’s VP of Scientific Affairs, Josh Soldo, was selected for presentation at the conference. The title of - the paper is “Solving an Intractable Problem Mitigating Sample Specific Interferences in Clinical Samples Utilizing a Novel Surface Chemistry Approach”* .

Mr Soldo’s presentation was the subject of a patent application filed on 24[th] February, 2015 for the pre-analytical treatment of samples. The invention covers approaches for clearing or depleting interfering substances from pathology samples, prior to analytical testing. Mr Soldo’s AACC presentation discusses the clinical need and ongoing work toward the development of a pre-treatment product.

Mr Soldo will present at 10.30am on Tuesday 28 July EST in the Exhibit Hall, Theatre 2 as part of the AACC OEM Lecture Series. A copy of the presentation is attached.

Anteo exhibits at 2015 AACC Clinical Lab Expo

This week’s AACC Clinical Lab Expo is an important annual event for Anteo’s sales and marketing team. Anteo will be exhibiting its Mix&Go range of products and showcasing its IP at Booth 4564. The conference will provide an important opportunity for the team to meet with existing and potential partners and customers.

This year Anteo is promoting its association with Sigma Aldrich, Scienion and Qiagen at the conference. Further updates will be released via Anteo’s social media channels during the week.

==> picture [115 x 87] intentionally omitted <==

==> picture [268 x 55] intentionally omitted <==

==> picture [315 x 91] intentionally omitted <==

BRR audio-cast with Dr Geoff Cumming, CEO

Anteo invites investors to listen to an audio interview of CEO, Dr Geoff Cumming, where he provides further insights into recent announcements and an overview of Anteo’s participation in the AACC annual conference.

In this audiocast, Dr Cumming discusses:

• The recent announcement regarding the inclusion of Mix&Go products in the Sigma Aldrich product catalogue

• The IMRA collaboration which follows excellent results from the recent feasibility study – what it means, outputs and the key benefits for clinicians

• Anteo’s activities at AACC, including Mr Soldo’s AACC conference presentation

To listen to the audiocast, please copy the following link into your browser: http://brrmedia.com/event/139819

For further information, see our website (www.anteotech.com) or contact the persons outlined below.

outlined below.
Company	Media and Investor Relations
Dr Geoff Cumming, Chief Executive Officer T: + 61 7 3219 0085	Jane Lowe, IR Department E: jane.lowe@irdepartment.com.au T: + 61 411 117 774

About Anteo Diagnostics Limited

Anteo Diagnostics (ASX: ADO) uses its patented technology to develop, manufacture and commercialise proprietary surface coatings for use in healthcare, life sciences and beyond. Its patented technology is applied in the Mix&Go product range, which delivers solutions to the challenges of establishing highly functional interfaces between fragile biomolecules, and synthetic, and often incompatible materials.

==> picture [596 x 138] intentionally omitted <==

==> picture [720 x 127] intentionally omitted <==

Solving an Intractable Problem Mitigating Sample Specific Interferences in Clinical Samples Utilizing a Novel Surface Chemistry Approach

The Surface You Want on the Surface You Have

==> picture [720 x 55] intentionally omitted <==

Interference

• Interference"is"a"substance"present"in"a"pa0ent"specimen"that"can"alter" the"correct"value"of"the"result"by"interfering"with"an0body"binding,"or"that" can" increase" or" decrease" assay" signal" by" bridging," steric" hindrance," or" autoan0body"mechanisms."

• Erroneous"results"can"impact"pa0ent"care,"and"can"lead"to"unnecessary" invasive,"diagnos0c"or"therapeu0c"procedures,"or"failure"to"treat"a"pa0ent" with"a"false"nega0ve"test"result"

2"

==> picture [720 x 55] intentionally omitted <==

Clinical Need

==> picture [589 x 110] intentionally omitted <==

----- Start of picture text -----

The"global"immunoassay"
Up to" 10%billion% laboratory" By"2018"
instruments"and"reagents"
tests"are"performed"each"year"
market"is"expected"to"reach"
in"US"alone"
$19.1%Billion%%
----- End of picture text -----

result%in%erroneous%test%results%and%lead%to%unfavorable%pa?ent%outcomes%

==> picture [35 x 42] intentionally omitted <==

There%Is%a%Clinical%Need%For:%

mi0gate"interference"without"impac0ng"laboratory"work"flow"and"turnaround"0me," and"without"altering"or"changing"the"sample"composi0on"to"enable"laboratories"to" report"pa0ent"results"to"physicians"aJer"such"preKtreatment"

3"

==> picture [720 x 55] intentionally omitted <==

Common Diagnostic Immunoassay Formats Used Today

• Double"an0body"sandwich"assays"

• The"amount"of"an0gen"present"in"the"pa0ent"sample"is"directly"propor0onal" to"the"amount"of"rela0ve"light"units"(RLU)"or"signal"detected"by"the"system""

• Compe00ve"inhibi0on"assays"

• An"inverse"rela0onship"exists"between"the"amount"of"an0gen"present"in"the" pa0ent"sample"and"the"amount"of"RLU"or"signal"detected"by"the"system""

• Delayed"capture"assays"

• The" capture" an0body" is" labeled" with" a" tag" (i.e." bio0n," for" subsequent"capture"by"an"an0Ktag"solid"phase"

• Assay" signal" is" dependent" on" successful" capture" of" the" tagKlabeled" capture" an0body"by"the"an0Ktag"solid"phase"

4"

==> picture [720 x 55] intentionally omitted <==

Double Antibody Sandwich Assay Formats

==> picture [465 x 249] intentionally omitted <==

• A.

• B.

• C. Both"the"conjugate"and"capture"an0body"bind"an0gen"at"the"same"0me"

5"

==> picture [720 x 55] intentionally omitted <==

Competitive Inhibition Assay Formats

==> picture [481 x 249] intentionally omitted <==

• A. Conjugate"and"an0gen"compete"for"capture"an0body"(true"compe00on)"

• B. second"incuba0on"to"bind"to"capture"an0body"(backfill"or"piggyback)"

6"

==> picture [720 x 55] intentionally omitted <==

Delayed Capture Assay Formats

==> picture [464 x 262] intentionally omitted <==

• A. The"conjugate"and"capture"an0body"bind"an0gen"and"form"a"solu0onKbased"sandwich,"and"a"SAv"coated"solid" phase"binds"to"the"bio0n"tag"on"the"capture"an0body"

• B. Capture"an0body"binds"an0gen,"a"SAv"coated"solid"phase"binds"to"the"bio0n"tag"on"the"capture"an0body,"and" Conjugate"forms"a"sandwich"with"the"capture"an0bodyKan0gen"complex"

7"

==> picture [720 x 55] intentionally omitted <==

HAAA and MASI

• Human" an0Kanimal" an0bodies" ( HAAA interference"( MASI )"are"the"most"troublesome"and"problema0c"as"they" are"difficult"to"detect"and"can"dras0cally"affect"pa0ent"management."

• HAAA" interference" includes" human" IgG" and/or" IgM" with" specificity" or" avidity"to"bovine,"goat,"mouse,"rabbit,"and"sheep"IgG,"and"RF"interference" with"specificity"to"the"Fc"region"of"an0bodies"

• the"assay"design"or"formula0on"such"as"the"tracer"(ABEI,"acridinium"ester," ALP," HRP," ruthenium)," assay" specific" proteins" (streptavidin," an0body)," assay"tags"(bio0n,"fluorescein),"and"conjuga0on"spacers/linkers"(i.e."NHSK LC," NHSKLCKLC," NHSKPEO(n))" used" to" abach" the" tracer" or" tag" to" the" an0body,"analyte,"carrier"protein,"or"conjugate"scaffold."

8"

==> picture [720 x 55] intentionally omitted <==

HAAA Bridging

==> picture [464 x 248] intentionally omitted <==

• A.

• B.

• C.

9"

==> picture [720 x 55] intentionally omitted <==

HAAA Steric Hindrance

==> picture [464 x 248] intentionally omitted <==

• A. HAAA"binds"capture"an0body"and"interferes"with"conjugate"and"an0gen"binding.""

• B.

10"

==> picture [720 x 55] intentionally omitted <==

MASI Competition

==> picture [464 x 262] intentionally omitted <==

• A. Free"bio0n"binds"to"SAv"bio0n"binding"sites"and"competes"for"binding"of"the"bio0nKlabeled"capture"an0body" and"sandwich"complex"

• B. Free"bio0n"binds"to"SAv"bio0n"binding"sites"and"competes"for"binding"of"the"bio0nKlabeled"capture"an0body" prior"to"the"final"assay"incuba0on"and"conjugate"addi0on"

11"

==> picture [720 x 55] intentionally omitted <==

Mix&Go™

• Anteo" Technologies" and" its" family" of" patented" and" patent" pending" Mix&Go" formula0ons," processes" and" applica0ons" is" now" posi0oned" to" successfully" coat" surfaces" with" a" range" of" hydrophilic/hydrophobic" profiles"for"the"subsequent"gentle"and"secure"binding"of"proteins.

==> picture [554 x 128] intentionally omitted <==

• Mix&Go" is" a" Cr(III)Kbased" hard" Lewis" metal" ion" metal" polymer" that" chelates" to" or" electron" and" acts" a" oxygen" species" dona0ng" groups"

• “molecular"Velcro”."

• With"Mix&Go"even"“tricky”"and"very"fragile"proteins"can"be"coupled"to" surfaces"with"high"func0onality."

12"

==> picture [720 x 55] intentionally omitted <==

Serum Depletion to Mitigate Interference

• As"a"plaiorm"technology"Mix&Go"can"be"used"to"func0onalize"a"plethora" of" different" surfaces" for" subsequent" binding" and" coKcoa0ng" of" highly" func0onal"proteins"to"preKtreat"clinical"samples"and"deplete"interference."

• Examples"include:"

• Paramagne0c"micropar0cles"

• Secondary"transfer"tubes"

• PoC"Flow"channels"

13"

==> picture [720 x 55] intentionally omitted <==

Magnetic Particle Serum Depletion

==> picture [431 x 322] intentionally omitted <==

the"STT"to"bind"and"deplete"an0KMab"IgM,"an0KALP"IgG,"and"free"bio0n"interference."

14"

==> picture [720 x 55] intentionally omitted <==

Secondary Transfer Tube Serum Depletion

==> picture [439 x 308] intentionally omitted <==

and"dispensed"to"the"AMG"STT,"the"blockers"coated"on"the"AMG"STT"surface"bind"and"deplete"an0KMab"IgM,"an0K ALP"IgG,"and"free"bio0n"interference"

15"

==> picture [720 x 55] intentionally omitted <==

Filtration Membrane Serum Depletion

==> picture [455 x 315] intentionally omitted <==

sample"is"added"to"the"AMG"filter"plate"and"passes"through"the"AMG"filter"membrane"or"resin,"the"blockers"coated" on"the"AMG"filter"bind"any"an0KMab"IgM,"an0KALP"IgG,"and"free"bio0n"and"deplete"interference.""

16"

==> picture [720 x 55] intentionally omitted <==

Flow Channel Serum Depletion

==> picture [569 x 256] intentionally omitted <==

----- Start of picture text -----

1
Sample
AMG Sample Channel
( pre-depletion )
2
Sample Interference Depleted Sample
Bound to Channel
AMG Sample Channel
( post-depletion )
Flow
Flow
----- End of picture text -----

sample"is"added"to"the"POCT"device"and"passes"through"the"AMG"sample"channel,"the"blockers"coated"on"the"AMG" sample"channel"bind"any"an0KMab"IgM,"an0KALP"IgG,"and"free"bio0n"and"deplete"interference.""

17"

==> picture [720 x 55] intentionally omitted <==

Assay Blocking Threshold Concept

==> picture [495 x 291] intentionally omitted <==

The"concept"that"MFG"have"designed"their"assays"to"mi0gate"known"mechanisms"of"heterophilic"an0body"and" assayKspecific"interference"regardless"of"the"0ter"(concentra0on),"avidity"(abrac0on"or"affinity"to"the"assay" reagents),"and"mechanism(s)"can"be"referred"to"as"the"Assay"Blocking"Threshold"(ABT).""

18"

==> picture [720 x 55] intentionally omitted <==

Accurate Immunoassay Results after AMG Serum Depletion

• Since"immunoassays"are"developed,"op0mized"and"validated"to"mi0gate" known" interference" mechanisms" based" on" the" ABT," a" Mix&GoKbased" sample" preKtreatment" solu0on" does" not" need" to" completely" deplete," remove"or"eliminate"interference"from"the"sample."""

• As"long"as"the"interference"0ter,"avidity"and/or"mechanism(s)"falls"within" the" ABT" aJer" sample" preKtreatment," the" assay" design" will" successfully" mi0gate"the"residual"sample"interference"and"report"an"accurate"pa0ent" result."

19"

==> picture [720 x 55] intentionally omitted <==

Summary

==> picture [56 x 84] intentionally omitted <==

All"immunoassays"are" suscep0ble"to"sample"specific" interference"that"can"result"in" erroneous"test"results"and"lead" to"unfavorable"pa0ent" outcomes"

There"is"a" CLINICAL%NEED% for"a" simple,"inexpensive," automatable"and"effec0ve" solu0on"to"mi0gate"sample" specific"interferences."

==> picture [55 x 84] intentionally omitted <==

Mix&GoJbased%serum%deple?on%surfaces%have:% The"poten0al"to"preKtreat" HUNDREDS%OF%MILLIONS% of"pa0ent"specimens" worldwide ," improve"the"quality"of"reported"pa0ent"results,"and"decrease"global"healthcare"costs"

20"

==> picture [720 x 55] intentionally omitted <==

==> picture [611 x 208] intentionally omitted <==

Joshua Soldo VP of Scientific Affairs joshua.soldo@anteotech.comt

anteotech.com Follow @anteotech +AnteoTechNews

21"